Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas.
Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas.
复制标题
DOI：
10.1016/j.ijid.2010.08.002
复制
发表时间：
2010-12
影响因子：
8.4
通讯作者：
Campbell, Thomas B.
中科院分区：
文献类型：
--
作者：
Firnhaber, Cynthia;Smeaton, Laura;Saukila, Nasinuku;Flanigan, Timothy;Gangakhedkar, Raman;Kumwenda, Johnstone;La Rosa, Alberto;Kumarasamy, Nagalingeswaran;De Gruttola, Victor;Hakim, James Gita;Campbell, Thomas B.
血液学异常是晚期白血病的常见表现， HIV-1感染可能影响高活性 抗逆转录病毒疗法（HAART）。尽管大多数HIV-1感染者 生活在资源有限的国家， 血液学异常如贫血，中性粒细胞减少， 和血小板减少症。这项研究比较了抗逆转录病毒治疗前的流行率 在一项随机试验中，1571名参与者的血液学异常， 非洲、亚洲、南美洲、加勒比海地区的抗逆转录病毒疗效， 美国.贫血、中性粒细胞减少和血小板减少的潜在协变量 在单变量分析中确定，并在单独的 每种血液学状况的多变量模型。中性粒细胞减少（中性粒细胞绝对计数≤ 1.3× 109/l），贫血（血红蛋白≤ 10 g/dl），和 血小板减少症（血小板≤ 125 × 109/l）， 开始抗逆转录病毒治疗的分别为14%、12%和 7%，且因国家而异（p < 0.0001）。在多变量模型中，贫血与 性别、血小板计数和国家;中性粒细胞减少症与 CD 4+淋巴细胞和血小板计数;血小板减少症 与国家、性别和慢性B型肝炎感染相关。治疗前血液学检查频率的差异 异常可能对选择 在资源有限的情况下提供抗逆转录病毒疗法。
Hematological abnormalities are common manifestations of advanced HIV-1 infection that could affect the outcomes of highly-active antiretroviral therapy (HAART). Although most HIV-1-infected individuals live in resource-constrained countries, there is little information about the frequency of hematological abnormalities such as anemia, neutropenia, and thrombocytopenia among individuals with advanced HIV-1 disease. This study compared the prevalence of pre-antiretroviral therapy hematological abnormalities among 1571 participants in a randomized trial of antiretroviral efficacy in Africa, Asia, South America, the Caribbean, and the USA. Potential covariates for anemia, neutropenia, and thrombocytopenia were identified in univariate analyses and evaluated in separate multivariable models for each hematological condition. The frequencies of neutropenia (absolute neutrophil count ≤ 1.3 × 109/l), anemia (hemoglobin ≤ 10 g/dl), and thrombocytopenia (platelets ≤ 125 × 109/l) at initiation of antiretroviral therapy were 14%, 12%, and 7%, respectively, and varied by country (p < 0.0001 for each). In multivariable models, anemia was associated with gender, platelet count, and country; neutropenia was associated with CD4+ lymphocyte and platelet counts; and thrombocytopenia was associated with country, gender, and chronic hepatitis B infection. Differences in the frequency of pretreatment hematological abnormalities could have important implications for the choice of antiretroviral regimen in resource-constrained settings.
登录
查看更多内容
影响因子：
3.8
作者：
Ciernik, IF;Cone, RW;Weber, R
通讯作者：
Weber, R
影响因子：
20.3
作者：
Moses, AV;Williams, S;Nelson, JA
通讯作者：
Nelson, JA
影响因子：
3
作者：
Huffam, S. E.;Srasuebkul, P.;Ditangco, R.
通讯作者：
Ditangco, R.
DOI：
10.1016/j.trstmh.2005.11.008
发表时间：
2006-08-01
影响因子：
2.2
作者：
Toure, Siaka;Gabillard, Delphine;Anglaret, Xavier
通讯作者：
Anglaret, Xavier
影响因子：
--
作者：
Levine, AM;Karim, R;Watts, DH
通讯作者：
Watts, DH